Omnicell Com (OMCL) Stock News

Omnicell (NASDAQ:OMCL) reported Q3 2024 results with total revenues of $282 million, down 5% year-over-year. GAAP net income was $9 million ($0.19 per diluted share), compared to $6 million ($0.12 per diluted share) in Q3 2023. Non-GAAP net income reached $26 million ($0.56 per diluted share). The company raised its 2024 non-GAAP EBITDA and earnings guidance, expecting full-year revenues between $1.100-1.110 billion and non-GAAP earnings per share of $1.65-1.72.

Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, has announced the release of its third quarter 2024 financial results. The results will be disclosed before market open on Wednesday, October 30, 2024. Following the release, the company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the financial outcomes.

Interested parties can participate in the live call by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for international locations, using the Conference ID 6944646. Additionally, a link to the live and archived webcast will be available on the Investor Relations section of Omnicell's website.

Omnicell, Inc. (Nasdaq: OMCL) has appointed Nnamdi Njoku as Executive Vice President and Chief Operating Officer, effective October 7, 2024. In this newly created role, Njoku will lead the company's global operations, reporting to Randall Lipps, chairman, president, CEO, and founder of Omnicell.

Njoku brings approximately 25 years of experience in leading global operations at healthcare and medical technology organizations. He most recently served as President of Sports Medicine, Surgical, Upper Extremities and Restorative Therapies at Zimmer Biomet Holdings, Inc. Previously, he spent over 18 years at Medtronic plc, where he led a $2 billion Neuromodulation Operating Unit.

Omnicell, a leader in transforming the pharmacy care delivery model, expects Njoku's expertise to help scale pharmacy automation and drive multi-year innovation and excellence.

Omnicell (Nasdaq: OMCL) has unveiled its Central Med Automation Service, a subscription-based solution designed to help health systems optimize centralized medication management. This service integrates enterprise-wide robotics, smart devices, and intelligent software with expert services to streamline medication dispensing from central fulfillment areas throughout health system enterprises.

Key components include the XR2 Automated Central Pharmacy System for advanced medication storage and dispensing, Central Pharmacy Manager software for workflow support, and Inventory Optimization Service for enterprise-wide inventory management. The service also provides ongoing expert guidance, on-site support, and performance tracking to ensure continuous operational optimization.

This solution aims to enhance inventory visibility, scalability, and patient safety while addressing challenges such as drug shortages and staffing issues in pharmacy operations.

Omnicell, a leader in pharmacy care delivery transformation, has announced its participation in the 2024 Wells Fargo Healthcare Conference. The company, trading under the Nasdaq symbol OMCL, will present on Thursday, September 5, 2024, at 1:30 p.m. ET.

This event provides an opportunity for investors and industry professionals to gain insights into Omnicell's strategies and innovations. Both live and archived webcasts of the presentation will be accessible through the company's investor relations website, offering wide-ranging access to interested parties unable to attend in person.

The conference, hosted by Wells Fargo, is a significant platform for healthcare companies to showcase their developments and future plans to the investment community.

EnlivenHealth, a division of Omnicell (OMCL), has launched a new Scope of Practice and Reimbursement Snapshot solution for Good Neighbor Pharmacy members. This innovative tool provides critical information on clinical services and reimbursement tailored to each state, empowering independent pharmacies to expand their clinical offerings and improve patient care.

The solution offers easy access to up-to-date information on approved clinical services, reimbursement activities, and medical billing codes. It aims to simplify the complex landscape of clinical services and billing, potentially driving operational efficiency and revenue growth for pharmacies. Good Neighbor Pharmacy members can access the solution through their AB Solutions Portal.

Omnicell (NASDAQ:OMCL) announced strong Q2 2024 results, exceeding guidance across all metrics. Total revenues were $277 million, down 7% year-over-year. GAAP net income was $0.08 per diluted share, while non-GAAP net income reached $0.51 per diluted share. The company reported $557 million in cash and cash equivalents and $571 million in total debt. Omnicell raised its 2024 non-GAAP EBITDA and earnings per share guidance, projecting full-year revenues between $1.070 billion and $1.110 billion. The company's XT Amplify program is gaining market momentum, and strategic partnerships are enhancing pharmacy performance. Omnicell remains focused on innovation and streamlining operations to drive long-term growth and shareholder returns.

Omnicell, Inc. (Nasdaq:OMCL), a leader in pharmacy care delivery transformation, has announced the release of its second quarter 2024 financial results on August 1, 2024, before the market opens. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. Interested parties can join the call by dialing (800) 715-9871 in the U.S. or (646) 307-1963 internationally, using the Conference ID 3278878. A live and archived webcast will be available on Omnicell's Investor Relations website.

Omnicell, Inc. (OMCL) will be presenting at the BofA Securities 2024 Health Care Conference in Las Vegas, NV. The presentation will take place on May 15, 2024, at 3:40 p.m. PT. The event will be live-streamed and available for viewing on the Omnicell website.